Bradanicline

Bradanicline (INN,[1] code name TC-5619) is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder. [2] Phase I clinical trials were completed successfully, and it was in phase II trials.[3]

Bradanicline
Clinical data
Other namesTC-5619
Identifiers
CAS Number
PubChem CID
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC22H23N3O2
Molar mass361.437 g/mol g·mol−1
3D model (JSmol)
  (verify)

In May 2011, AstraZeneca declined to exercise its right to license the compound.[4] In September 2012, Targacept ended its development of badanicline for the purpose of treating ADHD in adults.[5] It was being studied for cognitive and memory enhancement.[6]

Bradanicline was discontinued for Alzheimer's disease and cognitive impairment in schizophrenia in late 2013.[7] It was also discontinued for ADHD, and no longer seems to be being developed.[7]

References
  1. "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 73" (PDF). World Health Organization. pp. 68–9. Retrieved 3 January 2017.
  2. TC-5619 Cognitive Dysfunction in Schizophrenia Archived August 20, 2008, at the Wayback Machine
  3. Rethinking Schizophrenia
  4. Targacept retains full development rights for TC-5619
  5. Targacept ends development of ADHD drug
  6. "Statement on a Nonproprietary Name Adopted by the USAN Council" (PDF). November 27, 2013. Cite journal requires |journal= (help)
  7. "Bradanicline - Attenua - AdisInsight".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.